Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Haematologica. 2020 Jan 31;105(2):e80-e83. doi: 10.3324/haematol.2018.213314. Print 2020.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't